

Preliminary Programme



NOVEMBER 30 - DECEMBER 1, 2018

# IOF REGIONAL SYDNEY'18

7<sup>TH</sup> ASIA-PACIFIC OSTEOPOROSIS CONFERENCE

ICC SYDNEY

[www.iof-regional.org](http://www.iof-regional.org)

**Organizer**  
International Osteoporosis Foundation

**Secretariat**  
[www.humacom.com](http://www.humacom.com)

Submit your  
abstract now!

## PRE-CONFERENCE COURSE

ACU North Sydney Campus

Nov 28 – 29, 2018

Osteoporosis: Essentials of Densitometry,  
Diagnosis and Management Course

 [facebook.com/iofbonehealth](https://facebook.com/iofbonehealth)

 [instagram.com/worldosteoporosiday](https://instagram.com/worldosteoporosiday)

 [twitter.com/iofbonehealth](https://twitter.com/iofbonehealth)

 [youtube.com/iofbonehealth](https://youtube.com/iofbonehealth)



Our vision is a world without  
fragility fractures in which  
healthy mobility is a reality for all.  
 [www.iofbonehealth.org](http://www.iofbonehealth.org)



## Information

1. The Pre-Conference Courses will take place at the ACU (Australian Catholic University)
2. The Pre-Conference Courses can be booked separately or as part of the entire congress registration
3. The Opening Ceremony will take place at the ICC Sydney (International Convention Centre Sydney)
4. The Opening Ceremony is open to all duly registered delegates
5. The Exhibition Area is open on Friday from 08.30 to 18.00 and on Saturday from 08.00 to 17.00



## Pre-Conference Courses

### OSTEOPOROSIS: ESSENTIALS OF DENSITOMETRY, DIAGNOSIS AND MANAGEMENT COURSE

#### Wed, November 28 13.30 - 17.10

- 13.30 • *Welcome and Opening Remarks* – N. Pocock and A. Mithal
- 13.40 • *Overview of Osteoporosis* – N. Pocock
- 14.30 • *Bone Measurement Device Operating Principles* – S. Baldwin
- 15.20 *Coffee Break*
- 15.40 • *X-Ray Science, Radiation Safety and Quality Assurance* – N. Pocock
- 16.20 • *Clinical Evaluation of Bone Health* – D. Chan

#### Thu, November 29 08.00 - 17.00

- 08.00 • *Use of Bone Densitometry for the Diagnosis of Osteoporosis* – J. Center
- 08.50 • *Fracture Risk Assessment* – S. Baldwin
- 9.40 • *Monitoring Treatment of Osteoporosis* – J. Wark
- 10.30 *Coffee Break*
- 10.50 • *Clinical Management Part 1: Non-Pharmacologic, Estrogen & SERM Treatment* – S. Ferrari
- 11.40 • *Clinical Management Part 2: Pharmacological Treatment Continued* – J. Center



- 12.30     *Lunch Break*
- 13.30     • *Clinical Management Part 3: Further Pharmacologic Treatment Considerations*  
              – M. Chandran
- 14.20     • *Principles of DXA Scan Interpretation* – N. Pocock
- 15.10     *Coffee Break*
- 15.30     • *Principles of Reporting DXA Scans* – N. Pocock
- 16.20     • *Cases for Discussion* – N. Pocock

**Conference (ICC Sydney)**

**Thu, November 29**

Fri, November 30

Sat, December 1

17.30     **OPENING CEREMONY**

- *Welcome* – C. Cooper, J. A. Kanis & M. Chandran
- *Best clinical papers of 2018* – R. Rizzoli
- *Inclusion of diversity in science* – S. Brennan Olsen
- *Hearing the Consumer voice* – G. Lyubomirsky
- *Osteoporosis, global challenge, local impacts* – L. March
- *Conclusion*

19.30     **WELCOME COCKTAIL**

20.30


**Conference (ICC Sydney)**

Thu, November 29

**Fri, November 30**

Sat, December 1

 08.00 **EXHIBITION AREA OPEN**

19.00

**08.15 PLENARY SESSION I**
*Improving the identification of high risk patients*

Chair: J. A. Kanis &amp; E. Seeman

- *Can FRAX be improved* – J. A. Kanis
- *CTF/FLS: what have we achieved* – C. Cooper
- *New imaging modalities* – S. Ferrari

**9.30 ORAL COMMUNICATIONS SESSION I**

Chair: J. Eisman

- 9.30 – **OC1** – *T-SCORE AS AN INDICATOR OF FRACTURE RISK ON THERAPY: EVIDENCE FROM ROMOSUZUMAB VS ALENDRONATE TREATMENT IN THE ARCH TRIAL* – C. Tolman
- 9.40 – **OC2** – *DENOSUMAB COMPARED WITH RISEDRONATE IN GLUCOCORTICOID-TREATED SUBJECTS: RESULTS FROM THE FINAL 24-MONTH ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY* – C. Tolman
- 9.50 – **OC3** – *VITAMIN D SUPPLEMENTATION IN PREGNANCY: A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL* – R. Khadgawat

 10.00 **INDUSTRY-SPONSORED SATELLITE SYMPOSIUM** (Detailed programme on page 10)

**11.00 PLENARY SESSION II**
*Similarities and differences in fracture risk and treatments response: Asia vs West (IOF-OA session)*

Chair: C. Cooper (IOF) &amp; G. Lyubomirsky (OA)

- *BMD and other parameters of bone in Asia vs West* – K. Sanders
- *FRAX: intervention threshold in Asia vs West* – E. Lau
- *Response to osteoporosis treatment: is it the same in Asian and Caucasian (benefit/risk including AFF)* – P. Ebeling

 12.30 **INDUSTRY-SPONSORED LUNCH SYMPOSIUM** (Detailed programme on page 10)

 13.30 **BREAK AND POSTER VIEWING SESSION**



Conference (ICC Sydney)

Thu, November 29

Fri, November 30

Sat, December 1

14.00 **MEET-THE-EXPERT SESSIONS**

- *Recent Fracture: when and how to treat osteoporosis* – J.-K. Lee
- *Chronic renal failure: how to assess and manage bone fragility?* – P. Ebeling
- *Vitamin D: which & how much?* – A. Mithal
- *Protein intake and supplement in fracture patient* – R. Rizzoli

14.45 **PLENARY SESSION III**

*Quality of life in musculoskeletal diseases - ESCEO symposium*

Chair: R. Rizzoli & E. Biver

- *Introduction* – O. Bruyère
- *Assessment of quality of life in osteoporosis* – J.-M. Kaufman
- *Assessment of quality of life in osteoarthritis* – C. Cooper
- *Assessment of quality of life in sarcopenia* – F. Buckinx
- *Discussion & Conclusion*

16.15 **INDUSTRY-SUPPORTED SESSION: IOF - APOA JOINT SESSION**  
(more information on page 10)

*Osteoporosis - Orthopedic Surgery in Asia Pacific, The Missing Link?*

- *Introduction* – S. Ferrari
- *Osteoporosis in Asia Pacific* – P. Ebeling
- *Orthopedic Surgery in Asia Pacific* – D. Choon
- *IOF-APOA Collaboration - "The Link"* – J. K. Lee
- *Launch of the IOF-APOA collaboration and Promising Future* – C. Cooper

17.00 **ORAL COMMUNICATIONS SESSION II**

Chair: M. Chandran

- 17.00 – **OC4** – *ANTI-OSTEOPOROSIS MEDICATIONS ARE ASSOCIATED WITH DECREASED MORTALITY AFTER HIP FRACTURE* – Y. Li
- 17.10 – **OC5** – *ASIA-PACIFIC BONE ACADEMY FRACTURE LIAISON SERVICE EDUCATIONAL INITIATIVE* – P. Ebeling
- 17.20 – **OC6** – *INCREASED CORTICAL POROSITY AND REDUCED TRABECULAR DENSITY ARE NOT NECESSARILY SYNONYMOUS WITH BONE LOSS AND MICROSTRUCTURAL DETERIORATION* – E. Seeman



Conference (ICC Sydney)

Thu, November 29

**Fri, November 30**

Sat, December 1

17.30 **CNS ROUNDTABLE**

*Mapping calcium intake*

Chair: B. Dawson-Hughes & A. Mithal

- *Dietary calcium intake worldwide (Ca map) – B. Dawson-Hughes*
- *Consequences of low calcium intake in the Asia Pacific region – R. Rizzoli*
- *Calcium supplements and fracture prevention – A. Mithal*
- *Calcium intake and its implication in China – W. Xia*
- *Roundtable: Potential strategies to improve calcium intake  
- What is feasible within the low intake countries*

19.00



Conference (ICC Sydney)

Thu, November 29

Fri, November 30

Sat, December 1

08.00 EXHIBITION AREA OPEN

17.00

08.15 MEET-THE-EXPERT SESSIONS

- Falls prevention: is it possible – W.-L. Hsu
- Bone loss in early menopause: to treat or not? – A. Vincent
- Genetic markers of bone fragility: what have we learned – E. Duncan
- Can we trust bone turnover markers to improve fracture assessment – H. Morris

09.00 PLENARY SESSION IV

*Assessment and management of bone fragility beyond idiopathic osteoporosis (IOF-ANZBMS session)*

Chair: E. Biver & P. Croucher (ANZBMS)

- Fracture prevention in cancer patients – E. Biver
- Fracture prevention in diabetes patients – M. Chandran
- When to suspect a genetic disorder? – J. Eisman

10.15 ORAL COMMUNICATIONS SESSION III

Chair: J. Center

- 10.15 – **OC7** – EFFECTS OF TERIPARATIDE ON HIP AND UPPER LIMB FRACTURES IN PATIENTS WITH OSTEOPOROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS – M. Hassanzai
- 10.25 – **OC8** – DIGITAL X-RADIOGRAMMETRY COMBINED WITH MAMMOGRAPHY TO SCREEN POSTMENOPAUSAL WOMEN FOR REDUCED BONE MINERAL DENSITY – A. Rao
- 10.35 – **OC9** – DO DEFINITIONS OF SARCOPENIA PREDICT FRACTURE RISK INDEPENDENT OF FRAX, FALLS AND BMD? (A META-ANALYSIS OF THE OSTEOPOROTIC FRACTURES IN MEN (MROS) STUDY) – H. Johansson
- 10.45 – **OC10** – ASSESSING CLINICAL UTILITY (IMPACT) OF GENETIC PROFILING IN FRACTURE RISK ASSESSMENT: A DECISION CURVE ANALYSIS APPROACH – T. Ho-Le


**Conference (ICC Sydney)**

Thu, November 29

Fri, November 30

**Sat, December 1**
**11.00 PLENARY SESSION V**
*New insights in the management of knee osteoarthritis - ESCEO Symposium*

Chair: C. Cooper &amp; F. Cicuttini

- Welcome – C. Cooper
- The 2014-2016 ESCEO algorithm for the management of knee osteoarthritis – O. Bruyère
- New insights on the safety of anti-osteoarthritis medications – E. Dennison
- New clinical evidence supporting the use of SYSADOAs as a first-line background treatment in knee osteoarthritis – J.-Y. Reginster, G. Honvo, A. Geerinck, O. Bruyère
- Update of the 2014-2016 ESCEO algorithm for the management of knee osteoarthritis – C. Cooper
- Discussion & Conclusion – C. Cooper

**12.30 INDUSTRY-SPONSORED SATELLITE SYMPOSIUM (Detailed programme on page 10)**
**13.30 BREAK AND POSTER VIEWING SESSION**
**14.00 IOF-OA-ANZBMS JOINT SESSION**

Chair: G. Lyubomirsky &amp; B. Dawson-Hughes

- Exercise and osteoporosis – B. Beck
- Monetary cost of osteoporosis – J. A. Kanis
- Morbidity and mortality of osteoporosis – J. Center

**14.45 IOF-AGNOVOS HEALTHCARE YOUNG INVESTIGATOR AWARDS**

Chair: A. Mithal

- 14.51 – **P118** – ORAL BISPHOSPHONATE USE AND ALL-CAUSE MORTALITY IN PATIENTS WITH ADVANCED (STAGE IIIB+) CHRONIC KIDNEY DISEASE: A POPULATION-BASED COHORT STUDY – D. Alarkawi
- 15.00 – **P050** – PREDICTION OF FRACTURES IN MEN WITH DYSGLYCAEMIA USING FRAX (AUS) – K. Holloway-Kew
- 15.09 – **P137** – ATYPICAL FEMUR FRACTURES IN AN AUSTRALIAN HOSPITAL SETTING: INCIDENCE, PATIENT RISK FACTORS AND DENSITOMETRIC CHARACTERISTICS – H. Nguyen
- 15.18 – **P046** – ASSOCIATIONS BETWEEN PAIN AT MULTIPLE SITES AND PREVALENT AND INCIDENT FRACTURES IN OLDER ADULTS – F. Pan
- 15.27 – **P011** – MID-CALF SKELETAL MUSCLE DENSITY AND ITS ASSOCIATIONS WITH ACCELEROMETER-DETERMINED PHYSICAL ACTIVITY, BONE HEALTH AND INCIDENT 12-MONTH FALLS IN OLDER ADULTS: THE HEALTHY AGEING INITIATIVE – D. Scott
- 15.36 – **P083** – PERSISTENT HIGH-IMPACT ACTIVITY AND FITNESS DURING ADOLESCENCE AND EARLY ADULTHOOD AND BONE DENSITY AND MICROARCHITECTURE IN EARLY ADULTHOOD – Y. Yang





**Conference (ICC Sydney)**

Thu, November 29

Fri, November 30

**Sat, December 1**

14.45 **MEET-THE-EXPERT SESSIONS**

- *Osteosarcopenia* – G. Duque
- *Glucocorticoid osteoporosis* – E. Dennison
- *Assessment of physical strength and performance* – F. Buckinx

15.45 **PLENARY SESSION VI**

*Osteoporosis treatment: update*

Chair: J. K. Lee & S. Ferrari

- *Benefit/Risk of long term treatment* – S. Ferrari
- *Fracture risk off therapy* – E. Dennison
- *Closing the gap in the treatment of patients at imminent risk of fracture: role of the new anabolic agents* – E. Biver

17.00



## Industry-Sponsored Sessions

Thu, November 29	Fri, November 30	Sat, December 1
	<p><b>MEDTRONIC SATELLITE SYMPOSIUM</b></p> <p><i>UNDERSTANDING MORTALITY RISK FOR PATIENTS WITH VCF</i> Chair: K. L. Ong</p> <ul style="list-style-type: none"> <li>• <i>Understanding mortality risk for patients with VCF</i> – K. L. Ong</li> </ul>	
	<p><b>AMGEN SATELLITE SYMPOSIUM</b></p> <p><i>ACHIEVING THE GOALS OF OSTEOPOROSIS THERAPY</i></p> <ul style="list-style-type: none"> <li>• <i>Arrivals and welcome</i> – P. Ebeling</li> <li>• <i>Presentation and Q &amp; A</i> – S. Ferrari</li> <li>• <i>Long term treatment – case study</i> – P. Ebeling</li> <li>• <i>Panel discussion</i> – All</li> </ul>	
	<p><b>IOF-APOA JOINT SESSION SUPPORTED BY AGNOVOS HEALTHCARE</b></p> <p><i>Osteoporosis - Orthopedic Surgery in Asia Pacific, The Missing Link?</i></p> <ul style="list-style-type: none"> <li>• <i>Introduction</i> – S. Ferrari</li> <li>• <i>Osteoporosis in Asia Pacific</i> – P. Ebeling</li> <li>• <i>Orthopedic Surgery in Asia Pacific</i> – D. Choon</li> <li>• <i>IOF-APOA Collaboration - "The Link"</i> – J. K. Lee</li> <li>• <i>Launch of the IOF-APOA collaboration and Promising Future</i> – C. Cooper</li> </ul>	

Thu, November 29	Fri, November 30	Sat, December 1
		<p><b>ELI LILLY SATELLITE SYMPOSIUM</b></p> <p><i>THE IMPORTANCE OF BONE FORMING AGENTS IN THE TREATMENT OF SEVERE OSTEOPOROSIS</i> Chairperson: D. Thiebaud</p> <ul style="list-style-type: none"> <li>• <i>Welcome &amp; Introduction</i> – D. Thiebaud</li> <li>• <i>Differing Effects of Antiresorptive and Anabolic Therapies on Bone Structure</i> – E. Seeman</li> <li>• <i>Differential Effects of Teriparatide VS Antiresorptives on Osteoporotic Fractures</i> – S. Ferrari</li> <li>• <i>Audience Questions and Answers</i> – All Panel</li> <li>• <i>Closing Remarks</i> – D. Thiebaud</li> </ul>